Description du projet
La menace de la peste porcine africaine prend de l’ampleur
La peste porcine africaine (PPA) est rapidement passée du statut de maladie exotique à celui de menace mondiale pour les suidés domestiques et sauvages (dont les porcs, les sangliers et les sangliers sauvages). L’Europe fait face à différents scénarios de peste porcine africaine, allant d’apparitions sporadiques à des épidémies généralisées, particulièrement difficiles à gérer dans les élevages de sangliers et les petits élevages de jardin. Si les méthodes de lutte conventionnelles se révèlent efficaces dans les exploitations porcines industrielles, elles ne parviennent toutefois pas à circoncire la maladie dans les populations sauvages ou les petites exploitations. Le projet ASFaVIP financé par l’UE se propose de combler cette lacune en testant des vaccins prometteurs, dont l’ASFV-G-ΔI177L, qui s’est révélé efficace au Vietnam. Il procédera à des tests de sécurité et d’efficacité, caractérisera la réponse immunitaire et optimisera les stratégies de vaccination. Ces données sont essentielles pour évaluer les avantages et les risques liés au déploiement des vaccins contre la PPA.
Objectif
"African swine fever (ASF) has recently transformed from an exotic disease to a panzootic threat to domestic and wild suids world-wide. Europe is currently facing different scenarios with front and point introductions, affected wild boar and domestic pig populations, epidemic and endemic situations. While our traditional prevention and control strategies work well with industrial pig farms, we quickly reach our limits when we have to control the disease in the abundant wild boar population or in regions with a majority of backyard farms. To turn the tide and to safeguard animal health, vaccines, especially oral vaccines for wild boar, could be the missing tool.
There has been considerable progress in vaccine development and while we should continue to look for alternative approaches, we must now also dare to test the promising candidates beyond simple proof-of-concept studies. Only in this way can we generate the data base for benefit-risk analysis of whether and how current generation vaccines could be employed.
Along these lines, this project sets out to test the vaccine candidate ""ASFV-G-ΔI177L"" in safety and efficacy tests after oral and intramuscular application as prescribed by international guidelines. This vaccine candidate has shown safety and very good protection under laboratory conditions and has been applied in the field in Vietnam. As a backup option, other promising candidates, “ASFV-G-ΔMGF” and “ASFV-G-Δ9GL/UK, will be tested in initial comparative trials. Accompanying the prescribed tests, our interdisciplinary consortium will characterize the protective immune responses, target the optimization of oral immunization and model tailored vaccination strategies. The data body generated in this project is crucial for benefit-risk-assessments at the level of all authorities entrusted with licensure and deployment of ASF vaccines and for this reason, relevant stakeholders will be involved from the start to guarantee full exploitation of our data."
Champ scientifique
Programme(s)
Régime de financement
HORIZON-RIA - HORIZON Research and Innovation ActionsCoordinateur
17493 Greifswald-Insel Riems
Allemagne